TNFAIP3 and systemic sclerosis: Accordingly, pharmacological approaches to augment endogenous A20 expression or function by blocking DREAM or by directly stimulating A20 expression via adiponectin receptor agonism might represent clinically viable therapeutic approaches in SSc and other intractable fibrosing conditions.